Hussein Arkhagha - Hikma Pharmaceuticals General Counsel
| HKMPY Stock | USD 49.81 0.70 1.39% |
Executive
Mr. Hussein Arkhagha is General Counsel of Hikma Pharmaceuticals Plc. Hussein has Group level responsibility for legal, regulatory and taxation related matters. During 17 years at Hikma, Hussein has held several legal leadership roles, including heading legal in MENA, the shareholders department and tax. Qualified lawyer in Jordan. Masters degree in International Business Law from the University of Manchester, under a UK Chevening Scholarship. since 2013.
| Tenure | 11 years |
| Phone | 44 20 7399 2760 |
| Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nyree Pinto | Tilray Inc | N/A | |
| Derek Glover | Viatris | N/A | |
| William Woodfield | Bausch Health Companies | N/A | |
| Donald Pearl | Bausch Health Companies | N/A | |
| Cees Heiman | Bausch Health Companies | N/A | |
| Theodora Mistras | Viatris | 42 | |
| Paul Surdez | Catalent | N/A | |
| JeanJacques Charhon | Bausch Health Companies | 59 | |
| Ramkumar Rayapureddy | Viatris | N/A | |
| Mitchell Gendel | Tilray Inc | 58 | |
| Roger Savell | Tilray Inc | 62 | |
| Seana Carson | Bausch Health Companies | 51 | |
| Philippe Martin | Viatris | 49 | |
| Lara Ramsburg | Viatris | N/A | |
| Josh Coyle | Bausch Health Companies | N/A | |
| Jiny MBA | Bausch Health Companies | 47 | |
| Aimee Lenar | Bausch Health Companies | N/A | |
| Randy Daigneau | Tilray Inc | N/A | |
| John MBA | Catalent | 69 | |
| Jennifer Mauer | Viatris | N/A | |
| Paul Campbell | Viatris | 57 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Engineer Darwazah, Ex CEO | ||
| Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
| Khalid Nabilsi, Chief Officer | ||
| CPA CFA, Exec MA | ||
| Brian Hoffmann, Pres Generics | ||
| Hussein Arkhagha, General Counsel | ||
| Samuel Park, Global US | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Majda Labadi, Corporate Vice President - Human Resources |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 110.13 M | |||
| Price To Earning | 10.10 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 2.55 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.